SCHEMBL25323447

SCHEMBL25323447

O=S(=O)(Oc1cccc2cccc(F)c12)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FABP1 P07148 1/20 0.39
DRD2 P14416 9/20 0.36
DRD3 P35462 6/20 0.36
HTR1D P28221 2/20 0.36
DRD4 P21917 4/20 0.35
HTR5A P47898 1/20 0.35
ALDH1A1 P00352 2/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HTT P42858 1/20 0.35
KMT2A Q03164 1/20 0.35
EPAS1 Q99814 1/20 0.35
CES2 O00748 1/20 0.34
BCHE P06276 1/20 0.34
CES1 P23141 1/20 0.34
MCL1 Q07820 1/20 0.34
DRD1 P21728 2/20 0.34
DRD5 P21918 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30404831 0.86 FABP1 (0.37) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL22554976 0.86 FABP1 (0.37) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL31405836 0.86 EPAS1 (0.35) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL25177557 0.86 EPAS1 (0.35) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL29889503 0.84 PDE4A (0.39) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL21315041 0.84 PDE4A (0.39) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL21315086 0.83 FABP1 (0.35) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL19948204 0.82 FABP1 (0.38) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL29428702 0.82 FABP1 (0.38) FABP1DRD2DRD3HTR1DDRD4
SCHEMBL29428689 0.81 DRD2 (0.38) FABP1DRD2DRD3HTR1DDRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4216951-B1 KRAS G12D INHIBITORS MIRATI THERAPEUTICS INC (US) 2026-04-01 EP disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
US-20230357277-A1 KRAS G12D INHIBITORS ARRAY BIOPHARMA INC. 2023-11-09 US disclosed
EP-4216951-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2023-08-02 EP disclosed
WO-2022066646-A1 KRAS G12D INHIBITORS Mirati Therapeutics, Inc. (US) 2022-03-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230357277-A1 KRAS G12D INHIBITORS KRAS, NRAS, HRAS FABP1 2438/4885DRD2 3963/4885DRD3 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.